Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.67 |
| ▸ | ABL1 | P00519 | 2/20 | 0.67 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.67 |
| ▸ | LCK | P06239 | 2/20 | 0.67 |
| ▸ | CSF1R | P07333 | 2/20 | 0.67 |
| ▸ | RET | P07949 | 2/20 | 0.67 |
| ▸ | MET | P08581 | 2/20 | 0.67 |
| ▸ | FLT1 | P17948 | 2/20 | 0.67 |
| ▸ | KDR | P35968 | 2/20 | 0.67 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.67 |
| ▸ | CLK2 | P49760 | 2/20 | 0.67 |
| ▸ | GSK3B | P49841 | 2/20 | 0.67 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.67 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.67 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.67 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.67 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.67 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3172318 | 0.87 | SMN1; SMN2 (0.50) | FGFR1MAP4K4ABL1NTRK1LCK | |
| SCHEMBL3163264 | 0.84 | FGFR1 (0.49) | FGFR1MAP4K4ABL1NTRK1LCK | |
| SCHEMBL6661733 | 0.84 | NPSR1 (0.57) | FGFR1LMNAHTTSMN1; SMN2CSNK2A2 | |
| SCHEMBL6663303 | 0.84 | SMN1; SMN2 (0.68) | FGFR1LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL6663533 | 0.84 | SMN1; SMN2 (0.68) | FGFR1MAP4K4ABL1NTRK1LCK | |
| SCHEMBL16801668 | 0.80 | FGFR1 (0.67) | FGFR1MAP4K4ABL1NTRK1LCK | |
| SCHEMBL14013968 | 0.80 | FGFR1 (1.00) | FGFR1MAP4K4ABL1NTRK1LCK | |
| SCHEMBL2368374 | 0.80 | SMN1; SMN2 (0.77) | FGFR1MAP4K4ABL1NTRK1LCK | |
| SCHEMBL2369475 | 0.80 | FGFR1 (0.67) | FGFR1MAP4K4ABL1NTRK1LCK | |
| SCHEMBL14669286 | 0.80 | FGFR1 (0.61) | FGFR1MAP4K4ABL1NTRK1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207174-B2 | Beta-3 adrenergic receptor agonists; urinary tract infections, incontinence, gastrointestinal disorders, dysmenorrhea, obesity; tocolytic, anxiolytic, antidiabetic agents; antidepressants; 4-(2-hydroxy-3-(1-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-ylamino)propoxy)phenol | 4SC AG (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-2118086-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEREOF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | 4SC AG (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-20080249114-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | SCHWARZ PHARMA AG (DE) | 2008-10-09 | — | — | US | disclosed |
| WO-2008090140-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEREOF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | 4SC AG (DE) | 2008-07-31 | — | — | WO | disclosed |
| EP-1947103-A1 | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments | 4SC AG (DE) | 2008-07-23 | — | — | EP | disclosed |
| US-20040138238-A1 | Substituted aminopyrimidine compounds as neurokinin antagonists | PREDIX PHARMACEUTICALS HOLDINGS, INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004014850-A2 | SUBSTITUTED AMINOPYRIMIDINES AS NEUROKININ ANTAGONISTS | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249114-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | ADRB3, ADRB1, ADRB2 | FGFR1 2950/4885MAP4K4 2383/4885ABL1 844/4885 |
| US-20040138238-A1 | Substituted aminopyrimidine compounds as neurokinin antagonists | TACR1, GRPR, BDKRB1 | FGFR1 792/4885MAP4K4 337/4885ABL1 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.